Roche / Genentech Patent-Cliff Exposure & CMS Drug Spending Portfolio
Roche / Genentech (South San Francisco, CA): 40 reconciled FDA prescription therapies (2.8% 2025 to 2030 cliff risk), $4.84B 2024 CMS Part D & Medicaid spend, and 53 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | South San Francisco, CA |
| Reconciled FDA Portfolio Therapies | 40 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 2.8% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $4.84B |
| 2024 Medicare Part D Spend | $1.63B |
| 2024 Medicaid Spend | $3.22B |
| California HCAI SB 17 Filings | 53 WAC filings (max 23.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.